Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Horizon Therapeutics plc

< Previous 1 2 3 4 5 6 Next >
Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2022 Financial Results on March 1, 2023
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Rule 15 (c) Announcement – Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Rule 17 (b) Announcement – Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Rule 17 (a) Announcement – Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population; Only Phase 2 Trial to Meet Primary Endpoint in Both Patient Populations
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Rule 2.12 Announcement – Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
UPLIZNA® (inebilizumab-cdon) Approved in Brazil for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Form 8.1 Opening Position Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Confirms Preliminary Discussions Regarding Potential Offer
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc to Participate in Upcoming Investor Healthcare Conferences in November
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Sustained Patient Response to KRYSTEXXA® (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance; Increases TEPEZZA and KRYSTEXXA Peak Annual Net Sales Expectations
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Named to the Seramount Inclusion Index
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
New Analysis of UPLIZNA® (inebilizumab-cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
New Real-World Analysis of TEPEZZA® (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Named to Newsweek’s 2022 Top 100 Most Loved Workplaces
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc to Release Third-Quarter 2022 Financial Results and Host Webcast on Nov. 2, 2022
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.